1 recruiting, 1 terminated. 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 4 | 1 | Terminated 1 |
Follow Mild Autonomous Cortisol Excess: new trials by email Literature Review of Mild Autonomous Cortisol Excess trials Research Report on Mild Autonomous Cortisol Excess
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Intervention 1: Adrenalectomy, Intervention 2: Semaglutide - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Not applicable | Recruiting | University of Texas Southwestern Medical Center | 75 | 2026-03-05 | 2026-03-27 |
| An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women Elagolix - Mild Autonomous Cortisol Excess | Phase 4 | Terminated | Icahn School of Medicine at Mount Sinai | 4 | 2021-07-06 | 2025-03-18 |
ACTH Syndrome, Ectopic (1) · Adrenal incidentaloma (1) · Cushing Syndrome (1) · Insulin Resistance (1) · Weight Loss (1)
Adrenal Gland Diseases (1) · Adrenocortical Hyperfunction (1) · Body Weight (1) · Body Weight Changes (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Hyperinsulinism (1) · Metabolic Diseases (1) · Neoplasms (1) · Nutritional and Metabolic Diseases (1) · Paraneoplastic Endocrine Syndromes (1) · Paraneoplastic Syndromes (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
elagolix (1)
Icahn School of Medicine at Mount Sinai (1) · University of Texas Southwestern Medical Center (1)
United States (2)
Alice C Levine (1)
K23DK142038 (1)